Megha Shah

Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson’s Disease: Post Hoc Analysis of a Randomized Trial

Angelo Antonini, Bruno Bergmans, Drew S. Kern, Florin Gandor et autres

INTRODUCTION: We evaluated continuous subcutaneously administered foslevodopa/foscarbidopa (LDp/CDp) in younger patients earlier within advanced Parkinson's disease (aPD). METHODS: This phase 3 trial included patients aged ≥ 30 years with levodopa-responsive PD, Mini-Mental State Examination score ≥ 24, and levodopa equivalent dose ≥ …

it, be, us, au, de, jp (code pays fourni par la source)

3482 Correlation between sleep and quality of life in people with parkinson’s disease treated with continuous subcutaneous infusion of foslevodopa/foscarbidopa

Irene A. Malaty, Eleni Okeanis Vaou, Robert A. Hauser, Bruno Bergmans et autres

Objectives To assess the correlation between sleep and quality of life (QoL) in people with Parkinson’s disease (PwP) receiving either oral levodopa/carbidopa immediate-release (LD/CD-IR) tablets or continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) for 12 weeks.Methods This post hoc analysis evaluated sleep …

us, be, se, gb (code pays fourni par la source)

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Jason Aldred, Manon Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau et autres

BACKGROUND: As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24-hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications. The feasibility and sustainability of LDp/CDp monotherapy warrants investigation. OBJECTIVE: The aim was to report the efficacy …

us, ca, dk (code pays fourni par la source)

Response to Foslevodopa/Foscarbidopa by Sex: Post Hoc Analyses of 2 Phase 3 Clinical Studies (P11-5.013)

Okeanis Vaou, Drew S. Kern, Irene A. Malaty, Per Odin et autres

Evaluate the sex-specific outcomes of people with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa(LDp/CDp).

us, se, dk (code pays fourni par la source)

Improvement of Troublesome Dyskinesia in People with Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa (P7-5.032)

Morten Blaabjerg, Tsao‐Wei Liang, Elizabeth Peckham, S. Elizabeth Zauber et autres

This post hoc analysis evaluated LDp/CDp efficacy by baseline duration of troublesome dyskinesia.

dk, us, se (code pays fourni par la source)

Improvement of “On” and “Off” Times in Patients with Advanced Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa: Subgroup Analyses from a Phase 3 Randomized Study (S30.007)

Drew S. Kern, Robert A. Hauser, Thomas Kimber, Okeanis Vaou et autres

To compare the efficacy of subcutaneous foslevodopa/foscarbidopa (LDP/CDP) with oral levodopa/carbidopa (LD/CD) across prespecified subgroups of patients with advanced Parkinson’s disease (PD) in a phase 3 study.

us, ca, au (code pays fourni par la source)

Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People with Parkinson’s (P9-3.005)

Robert A. Hauser, Bruno Bergmans, Irene A. Malaty, Daniel Cobb et autres

Assess whether 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) improves Parkinson’s Disease Sleep Scale-2 (PDSS-2) subdomains in people with Parkinson’s (PwP).

us, be, gb (code pays fourni par la source)

Treatment of Hypertension During Pregnancy and Lactation

Megha Shah, Vaibhavi Mulley, Fenil V Jethava, Shravan Kumar V Mali et autres

We all know due to the sedentary Lifestyle that all are sustaining, get exposed to many diseases and one of the serious diseases is hypertension. But this hypertension gets heavy-handed when it happens to a pregnant lady because it's not only risking …

in (code pays fourni par la source)

Is dronedarone really safer than amiodarone?

Megha Shah

in (code pays fourni par la source)